Recombinant human erythropoietin in the treatment of cisplatin-based-chemotherapy-induced a-nemia / 中国癌症杂志
China Oncology
;
(12)2001.
Artículo
en Chino
| WPRIM
| ID: wpr-675127
ABSTRACT
Purpose:
To study the efficiency and the safety of recombinant human erythropoietin (rHuEPO) in the treatment of chemotherapy-induced anemia.Methods:
41 tumor patients were randomized into two groupsEPO-treatment group and control group,in order to observe the changes of the haemoglobin level,transfusion requirement and quality of life for the two groups respectively.Results:
①the increase of haemoglobin level and the quality of life in the EPO-treat- ment group compared with that in the control group was statistically significant.②the reduction of transfusion requirement in the EPO-treatment group compared with that in the control group was not statistically significant.③treatment of EPO has few side-effects and a good tolerance.Conclusions:
rHuEPO in the treatment of chemotherapy-induced anemia is effec- tive and safe.Not only can it increase the haemoglobin level but also improve the quality of life for the patients,so it should be used widely.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Chino
Revista:
China Oncology
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS